DARZALEX 20 mg/mL concentrate for solution for infusion
Sponsors
Janssen - Cilag International, Celgene Corp., AbbVie Deutschland GmbH & Co. KG, Bristol-Myers Squibb Services Unlimited Company, Glaxosmithkline Research & Development Limited
Conditions
MSI Negative Colorectal CancerMSI Positive Colorectal CancerMultiple MyelomaMultiple myelomaMultiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.Newly diagnosed MM patients >= 65 years old or ineligible for autologous stem cell transplantPan tumorRelapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)
Phase 1
A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma
Active, not recruitingCTIS2023-506110-43-00
Start: 2018-01-25Target: 18Updated: 2025-11-28
A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Active, not recruitingCTIS2023-505219-19-00
Start: 2019-09-03Target: 86Updated: 2025-09-03
Phase 2
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
RecruitingCTIS2023-506914-32-00
Start: 2020-05-05Target: 307Updated: 2026-01-19
A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and
Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer
CompletedCTIS2024-516004-42-01
Start: 2014-05-14End: 2024-10-01Target: 143Updated: 2024-10-14
Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure - "Time is Kidney in the Treatment of myeloma Cast nephropathy" The TIKTAC phase II trial (Pilot-study)
Not yet recruitingCTIS2024-514702-31-00
Target: 50Updated: 2024-10-29
Phase 3
A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study
Active, not recruitingCTIS2022-500138-27-01
Start: 2023-02-28Target: 79Updated: 2025-09-24
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma
Active, not recruitingCTIS2023-510537-28-00
Start: 2020-05-15Target: 203Updated: 2025-10-30
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma
(RRMM) (KarMMa-3)
Active, not recruitingCTIS2023-509848-10-00
Start: 2019-06-12Target: 138Updated: 2025-11-28
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy
CompletedCTIS2024-510590-14-00
Start: 2023-03-03End: 2025-01-30Target: 400Updated: 2025-02-05
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingCTIS2024-511188-26-00
Start: 2024-12-20Target: 192Updated: 2025-09-12